Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs

[Guest guest]

http://www.jco.org/cgi/content/abstract/21/20/3859

 

Journal of Clinical Oncology, Vol 21, Issue 20 (October), 2003: 3859-3866

© 2003 American Society for Clinical Oncology

Dissemination of Information on Potentially Fatal Adverse Drug Reactions for

Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug

Events and Reports Project

Lisa A. Ladewski, Steven M. Belknap, Jonathan R. Nebeker, Oliver Sartor, E.

Allison Lyons, Timothy C. Kuzel, Martin S. Tallman, Dennis W. Raisch, Amy R.

Auerbach, Glen T. Schumock, Hau C. Kwaan, Charles L. Bennett

From the Veterans Affairs Midwest Center for Health Services and Policy

Research, Lakeside Division, the Division of Hematology/Oncology of the

Department of Medicine, the Center for Healthcare Studies, and the Robert H.

Lurie Comprehensive Cancer Center, Northwestern University Medical Center; the

Division of General Internal Medicine, Department of Medicine, The Feinberg

School of Medicine, Northwestern University; the Center for Pharmacoeconomic

Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL;

the Veterans Affairs Salt Lake City Health Care System and the University of

Utah School of Medicine, Salt Lake City, UT; the Stanley S. Scott Cancer Center

and Section of Hematology/Oncology, Louisiana State University Health Sciences

Center, New Orleans, LA; and the Veterans Affairs Cooperative Studies Program

Clinical Research Pharmacy Coordinating Center, University of New Mexico,

Albuquerque, NM.

Address reprint requests to Charles L. Bennett, MD, PhD, VA Lakeside Medical

Center, Division of Hematology/Oncology, Department of Medicine, 400 E Ontario

St, Suite 205, Chicago, IL 60611; e-mail: cbenne.

Purpose: To describe the clinical findings, occurrence rates, causality

evidence, and dissemination media for serious cancer drug–associated adverse

drug reactions (ADRs) reported in the postmarketing setting.

Methods: ADRs were termed serious if they resulted in death or severe organ

failure. ADR information for oncology drugs from package insert (PI) revisions,

so-called Dear Doctor letters, and journal articles was evaluated to identify

serious ADRs reported from 2000 to 2002. Timing and content of information

disseminated was assessed.

Results: Twenty-five serious ADRs associated with 22 oncology drugs were

identified after approval. Approximately half of these serious ADRs are

associated with drugs approved before 1995. ADRs were described in articles in

medical journals (17 ADRs), PI revisions (18 ADRs), and Dear Doctor letters (12

ADRs). PI revisions occurred less than 1 year after peer-reviewed publication

for four ADRs. These revisions often differed for similar ADRs that occurred

with drugs of the same class. Five of the seven ADRs lacking PI changes occurred

with off-label use, for which PI change is not recommended by US Food and Drug

Administration (FDA) policy. No cancer drug was withdrawn from the market during

the observation period.

Conclusion: Our findings demonstrate that serious ADRs may be discovered as long

as 36 years after a drug receives FDA approval. This suggests a need for

continued vigilance and efficient strategies for dissemination of information

about ADRs associated with cancer drugs.

Presented in part at the 39th Annual Meeting of the American Society of Clinical

Oncology, Chicago, IL, May 2003.

 

 

 

 

 

NEW WEB MESSAGE BOARDS - JOIN HERE.

Alternative Medicine Message Boards.Info

http://alternative-medicine-message-boards.info

 

 

 

Protect your identity with Mail AddressGuard